Related references
Note: Only part of the references are listed.Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
Peter Ellmark et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
The double edge of cancer immunotherapy
NATURE MEDICINE (2017)
Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
Omar A. Ali et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Kelly D. Moynihan et al.
NATURE MEDICINE (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
Yuka Miyoshi et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Fulminant type1 diabetes mellitus with anti-programmed cell death-1 therapy
Masahide Okamoto et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
Abhijit Ray et al.
ONCOTARGET (2016)
Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer
Sima Rahimian et al.
BIOMATERIALS (2015)
Antibody-drug conjugates as novel anti-cancer chemotherapeutics
Christina Peters et al.
BIOSCIENCE REPORTS (2015)
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
Eric F. Zhu et al.
CANCER CELL (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
Mahnaz Mellati et al.
DIABETES CARE (2015)
Immune Checkpoint Blockade in Cancer Therapy The 2015 Lasker-DeBakey Clinical Medical Research Award
James P. Allison
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
Danielle M. Lussier et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Intratumoral Immunization: A New Paradigm for Cancer Therapy
Aurelien Marabelle et al.
CLINICAL CANCER RESEARCH (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Growth Factors Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing
Mikael M. Martino et al.
SCIENCE (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
Marieke F. Fransen et al.
CLINICAL CANCER RESEARCH (2013)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott et al.
CLINICAL CANCER RESEARCH (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Tenascin C Promiscuously Binds Growth Factors via Its Fifth Fibronectin Type III-Like Domain
Laura De Laporte et al.
PLOS ONE (2013)
Fibronectin Binding Modulates CXCL11 Activity and Facilitates Wound Healing
Federico Tortelli et al.
PLOS ONE (2013)
Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix
Mikael M. Martino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Local immunomodulation for cancer therapy Providing treatment where needed
Marieke F. Fransen et al.
ONCOIMMUNOLOGY (2013)
Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
Marieke F. Fransen et al.
CLINICAL CANCER RESEARCH (2011)
Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Martina Steiner et al.
CLINICAL CANCER RESEARCH (2011)
Engineering the Growth Factor Microenvironment with Fibronectin Domains to Promote Wound and Bone Tissue Healing
Mikael M. Martino et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Microenvironmental regulation of metastasis
Johanna A. Joyce et al.
NATURE REVIEWS CANCER (2009)
Rig-I-/- mice develop colitis associated with downregulation of Gαi2
Yi Wang et al.
CELL RESEARCH (2007)
The heparin binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling
LA Maile et al.
MOLECULAR ENDOCRINOLOGY (2006)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice
MJI Ansari et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
